🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Munich
Clinical trial register · Germany

Clinical Trials in Munich, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Technical University of Munich31 Merck Sharp & Dohme LLC26 AbbVie22 Novartis Pharmaceuticals21 Ludwig-Maximilians - University of Munich21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Munich

405 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure
NCT06650995HFpEF - Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Technical University of Munich
Not applicable
40
Munich
2027-02-01
Not yet open
Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation
NCT07679568Acute Kidney Injury, Renal Failure
Fresenius Medical Care Deutschland GmbH
Observational
62
Munich
2026-11
Recruiting
Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
NCT05880524Ischemic Stroke, Inflammatory Response
DrugDornase Alfa
Ludwig-Maximilians - University of Munich
Phase 2
36
Munich, Berlin, Hamburg, Hanover
2026-10-01
Not yet open
PULSTA TPV Observational Study
NCT07747207Heart Disease
Taewoong Medical Co., Ltd.
Observational
200
Munich
2026-10
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Ulm, Wangen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne
2026-09-30
Not yet open
Evaluation of a Modularized Cognitive Behavioral Group Therapy Programme for Young Adults (CHANGE-Study)
NCT07772180Psychiatric Disorder
Max-Planck-Institute of Psychiatry
Not applicable
30
Munich
2026-09-03
Not yet open
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
NCT07762820Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1
Ludwig-Maximilians - University of Munich
Not applicable
75
Augsburg, Erlangen, Munich, Nuremberg
2026-09-01
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Augsburg, Berlin, Cologne, Munich
2026-09
Recruiting
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
NCT07674667Amyotrophic Lateral Sclerosis
Trace Neuroscience, Inc.
Phase 1/2
30
Munich, Rostock
2026-08-20
Recruiting
Evaluating a New Software (OTOGUIDE) to Help Monitor Electrode Insertion During Cochlear Implant Surgery.
NCT07690995Cochlear Implantation, Monitoring Electrode Insertion
MED-EL Elektromedizinische Geräte GesmbH
Not applicable
42
Munich
2026-08-18
Not yet open
Effectiveness of Clustered Versus Tapered Repetitive Transcranial Magnetic Stimulation (rTMS) as Maintenance Therapy Following Successful Acute rTMS Treatment in Patients With Depressive Syndrome
NCT07727005Major Depressive Disorder (MDD), Depressive Episodes, Depressive Syndrome
Technical University of Munich
Not applicable
100
Munich
2026-08-01
Recruiting
A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy
NCT07729982OPA1 Gene Mutation, Optic Atrophy, Autosomal Dominant
Ludwig-Maximilians - University of Munich
Observational
50
Munich
2026-07-16
Recruiting
HEARTBEAT-TROP. Polyethylene Glycol Precipitation to Unmask Macrotroponin
NCT07726420Diagnoses Disease
Technical University of Munich
Not applicable
160
Munich
2026-07-15
Recruiting
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
NCT07600476Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
Kupando GmbH
Phase 1
21
Munich, Würzburg, Münster
2026-07-03
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin
2026-06-03
Recruiting
HoLEP-ThuLEP - Comparing Lasers for BPH Surgery
NCT07565961BPH (Benign Prostatic Hyperplasia)
Ludwig-Maximilians - University of Munich
Not applicable
150
Munich
2026-06-01
Not yet open
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124Treatment Resistant Psychosis, Psychosis
University of Oxford
Phase 3
250
Berlin, Cologne, Munich
2026-06
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Reutlingen, Munich, Dresden, Berlin, Hamburg
2026-05-22
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
Munich, Göttingen, Bonn, Berlin
2026-05-14
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen
2026-05-11
Recruiting
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)
NCT07279649Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD), Isolated Artery Aneurysms (IAA), Trauma or Iatrogenic Vessel Injury
W.L.Gore & Associates
Observational
240
Munich
2026-05-08
Recruiting
Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study
NCT07479992Aortic Stenosis
Idoven 1903 S.L.
Observational
5,000
Bonn, Munich
2026-04-28
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Cologne, Giessen, Greifswald, Hamburg, Hanover, Munich
2026-04-23
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
DrugsZanzalintinib·Belzutifan
Merck Sharp & Dohme LLC
Phase 3
758
Augsburg, Munich, Jena, Berlin
2026-04-09
Recruiting
LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)
NCT07519811Hematologic Neoplasms, Oncologic Disorders
Technical University of Munich
Not applicable
150
Munich
2026-04-01
Not yet open
BCC-One-Stop-Study
NCT07482956Basal Cell Carcinoma
University Hospital Augsburg
Not applicable
290
Augsburg, Dresden, Erlangen, Munich
2026-04-01
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Munich, Hanover, Mainz
2026-03-26
Recruiting
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
160
Munich, Frankfurt am Main
2026-03-10
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Bochum, Düsseldorf
2026-03-10
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen
2026-03-09
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
Munich, Leipzig, Berlin, Dresden, Essen, Hamburg, Holstein, Karlsruhe
2026-02-24
Recruiting
TRICuspid Intervention and Invasive Hemodynamic Monitoring in Heart Failure
NCT07442903Heart Failure With Severe Tricuspid Regurgitation
LMU Klinikum
Not applicable
45
Munich, München
2026-02-17
By invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Observational
178
Berlin, Dresden, Marburg, Munich, Ulm
2026-01-29
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
NCT07358078Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Observational
2,000
Heidelberg, Munich, Münster
2026-01-09
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Ulm, Erlangen, Munich, Marburg, Essen, Dresden, Berlin, Hamburg
2026-01-06
Active, closed
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT07455097Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
600
Düsseldorf, Herne, Munich, Tübingen
2026-01-01
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Cologne, Dresden, Essen, Hamburg
2025-12-19
Recruiting
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
NCT07110038Penile Squamous Cell Carcinoma (PSCC)
DrugsAvelumab·Enfortumab Vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
25
Dresden, Düsseldorf, Mainz, Mannheim, Munich, Regensburg, Rostock, Tübingen
2025-12-16
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Munich, Würzburg
2025-12-11
Recruiting
Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
NCT06914544Prostate Cancer
University Hospital Schleswig-Holstein
Not applicable
175
Frankfurt am Main, Munich, Kiel, Erfurt
2025-12-10
Active, closed
Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device
NCT06799156Cataract, Vitrectomy, Vitrectomy Operation Under General Anesthesia
Beaver-Visitec International, Inc.
Observational
205
Munich
2025-12-03
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Munich, Potsdam, Frankfurt am Main, Kaiserslautern, Dresden, Bad Krozingen, Bad Oeynhausen, Berlin
2025-12-02
Not yet open
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
NCT06281847Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Advesya SAS
Phase 1/2
143
Munich, Ulm
2025-12
Recruiting
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
NCT07131956Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Recurrent
University of Erlangen-Nürnberg Medical School
Observational
200
Augsburg, Erlangen, Munich
2025-12
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
Berlin, Munich, Würzburg
2025-11-26
Recruiting
Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders
NCT07040189Multiple Myeloma, GI Cancer, Taste Disorders
Wuerzburg University Hospital
Not applicable
51
Munich, Regensburg, Würzburg
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Halle, Erfurt, Giessen
2025-11-11
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein
2025-11-05
Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Bochum, Frankfurt, Heidelberg, Leipzig, Lübeck, Munich
2025-11-03
Recruiting
Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy
NCT07077005Cardiomyopathy, Hypertrophic
Technical University of Munich
Not applicable
24
Munich
2025-11-01
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg
2025-10-17
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
48
Berlin, Frankfurt am Main, Munich
2025-10-16
Active, closed
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION
NCT07514520Alzheimer Disease, Neurodegenerative Diseases
Ludwig-Maximilians - University of Munich
Observational
100
Munich
2025-10-02
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz Aesthetics GmbH
Phase 3
300
Munich, Blankenfelde-Mahlow, Potsdam, Friedrichsdorf, Kassel, Bochum, Düsseldorf, Drensteinfurt
2025-10-01
Recruiting
Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App
NCT07212699Knee Osteoarthritis, Knee Arthroplasty, Hip Osteoarthritis, Hip Arthroplasty
Technical University of Munich
Not applicable
1,250
Munich
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Heidelberg, Nürtingen, Munich, Nuremberg, Regensburg, Hanover, Kiel, Jena
2025-09-30
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Munich, Cottbus, Herne, Ratingen, Berlin, Hamburg
2025-09-26
Active, closed
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07037875GERD (Gastroesophageal Reflux Disease)
DrugsLinaprazan glurate·Lansoprazole
Cinclus Pharma Holding AB
Phase 3
500
Mannheim, Dachau, Munich, Leipzig
2025-09-11
Recruiting
IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition
NCT07197138Depressive Disorder, Post-Acute COVID-19 Syndrome
Max-Planck-Institute of Psychiatry
Not applicable
42
Munich
2025-09-11
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110Plaque Psoriasis
AbbVie
Observational
700
Friedrichshafen, Kulmbach, Munich, Potsdam, Dortmund, Mainz, Mölln, Hamburg
2025-09-09
Active, closed
Spatiotemporal Associations Between the COVID-19 Pandemic and Cancer Diagnoses in Bavaria
NCT07008560Cancer
Bavarian Cancer Registry
Observational
438,000
Munich
2025-09-03
Not yet open
Global Survey on Newborns' HOspitalisation and Parental Experiences - the HOPE Study
NCT06827028Infant, Premature, Infant, Low Birth Weight, Parents, Life Change Events
Global Foundation for the Care of Newborn Infants
Observational
100
Munich
2025-09-01
Recruiting
BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specific Research Software
NCT06989580Heart Failure, Arrhythmia, Decompensated Heart Failure, Atrial Fibrillation
Biotronik SE & Co. KG
Not applicable
300
Munich
2025-08-22
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
Munich
2025-08-18
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugTeplizumab
Sanofi
Phase 3
723
Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich
2025-08-06
Recruiting
Robotic Assisted Right Colectomy With the DEXTER Robotic Surgery System
NCT07123051Right Colectomy
Distalmotion SA
Observational
33
Munich
2025-08-05
Recruiting
Harmony TPV EMEA PMS
NCT06906926Severe Pulmonary Valve Regurgitation
Medtronic Cardiovascular
Not applicable
80
Bad Oeynhausen, Berlin, Leipzig, Munich
2025-07-30
Recruiting
Real World Data Collection on the INSPIRIS RESILIA Aortic Valve
NCT07120048Aortic Valve Disease
Edwards Lifesciences
Observational
500
Heidelberg, Bad Neustadt an der Saale, Erlangen, Munich, Passau, Oldenburg, Bad Oeynhausen, Wuppertal
2025-07-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Heidelberg, Munich, Würzburg, Hamburg
2025-07-23
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
NCT07159607IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
LMU Klinikum
Observational
100
Munich
2025-07-17
Recruiting
Return to Sports After Knee Arthroplasty
NCT07183475Knee Osteoarthristis, Arthroplasty Replacement, Knee
Technical University of Munich
Not applicable
50
Munich
2025-07-15
By invitation
Virtual Reality-Augmented At-Home tDCS for Major Depression
NCT07146269Major Depression Moderate, Major Depression Severe
Technical University of Munich
Not applicable
30
Munich
2025-07-15
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Recruiting
Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly
NCT07504965Mild Cognitive Impairment, Mild Dementia
Ludwig-Maximilians - University of Munich
Observational
1,020
Munich
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsXeloda·Epirubicin·Adriamycin·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Erlangen, Munich, Paderborn, Koblenz, Saarbrücken, Berlin
2025-06-30
Active, closed
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531Primary Sjögren's Syndrome
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
180
Bad Doberan, Hamburg, Hanover, Heidelberg, Munich
2025-06-30
Recruiting
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
NCT06935591Atrial Fibrillation (AF)
Vektor Medical
Not applicable
423
Munich
2025-06-27
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
960
Munich, Offenbach, Rheine, Bendorf, Berlin, Darmstadt, Essen, Fürstenwalde
2025-06-23
Recruiting
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
NCT06513286Chronic Hepatitis B
Michael Hoelscher
Phase 1/2
81
Frankfurt, Hamburg, Hanover, Leipzig, Munich
2025-06-12
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
EURO-STIM Registry
NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
1,000
Hamburg, Lübeck, Magdeburg, Mannheim, Munich
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Recruiting
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830Hemophilia A
DrugEfanesoctocog alfa
Swedish Orphan Biovitrum
Phase 4
250
Berlin, Bonn, Frankfurt am Main, Hamburg, Munich
2025-05-21
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Lübeck
2025-05-13
Recruiting
Spontaneous Eye Blinking in Disorders of Consciousness
NCT06323031Disorders of Consciousness
Fondazione Don Carlo Gnocchi ETS
Observational
70
Burgau, Munich
2025-05-08
Recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
NCT06916507Parkinson's Disease
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-06
Recruiting
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329Progressive Pulmonary Fibrosis, Interstitial Lung Disease
University of Massachusetts, Worcester
Observational
500
Coswig, Mainz, Munich
2025-05-01
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel
2025-04-11
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Recruiting
Exercise in Triple- Negative Breast Cancer
NCT06672120Cancer, Breast
Technical University of Munich
Not applicable
120
Munich
2025-04-03
Active, closed
Functional and Structural Outcomes Following Childhood Bone or Soft Tissue Sarcomas of the Lower Extremity
NCT06737172Soft Tissue Sarcoma of the Lower Extremity, Bone Sarcoma of the Lower Extremity, Childhood and Adolescent Cancer
Technical University of Munich
Observational
18
Munich
2025-04-01
Recruiting
Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression
NCT07022171Depressive Disorder, Bipolar Disorder
Max-Planck-Institute of Psychiatry
Not applicable
86
Munich
2025-03-18
Recruiting
40 Hz Visual Stimulation as an Intervention in Schizophrenia
NCT06907420Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
Technical University of Munich
Not applicable
20
Munich
2025-03-14
Rows per page Showing 1–100 of 405
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/munich

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 405 of those studies with a site in Munich.

How many clinical trials are recruiting in Munich?

233 of the 405 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 12 have not yet opened recruitment, 149 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Munich), 405 studies
PhaseStudiesRecruitingShare
Observational1299231.9%
Phase 31155028.4%
Not applicable694517%
Phase 2572514.1%
Phase 1/216114%
Phase 2/3962.2%
Phase 1621.5%
Phase 4421%

Most active sponsors

Lead sponsors with the most studies (Munich)
Lead sponsorStudiesRecruiting
Technical University of Munich3123
Merck Sharp & Dohme LLC2613
AbbVie2210
Ludwig-Maximilians - University of Munich2115
Novartis Pharmaceuticals2111
Bristol-Myers Squibb134
LMU Klinikum1312
Deutsches Herzzentrum Muenchen65
Pfizer61
Regeneron Pharmaceuticals61
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.